IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity
Status:
Completed
Trial end date:
2016-03-30
Target enrollment:
Participant gender:
Summary
To compare the severity of retinopathy of prematurity (ROP) among treated infants with an
untreated control population, matched for gestational age at birth while confirming the dose
of rhIGF-1/rhIGFBP-3 is safe and efficacious.